TGFB1 and cirrhosis of liver: Inhibitory Smads, which inhibit TGF‐β signaling through multiple mechanisms, have shown good efficacy in keloids, diabetic kidney disease (DKD), liver cirrhosis, and myocardial infarction,148, 149, 150, 151 and may be a potential target of LTS.